Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cabotegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 17/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.85 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabotegravir SCHEMBL22584741 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL93097 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL18253200 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL18881147 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL81491 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL787358 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL29374458 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL10002356 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL19987969 | 0.99 | SLC22A2 (0.83) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL82533 | 0.99 | SLC22A2 (0.83) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636285-B2 | Method for treating HIV with cabotegravir and rilpivirine | VIIV HEALTHCARE COMPANY (US) | 2026-05-26 | — | — | US | claimed |
| US-12636286-B2 | Method for treating HIV with cabotegravir and rilpivirine | VIIV HEALTHCARE COMPANY (US) | 2026-05-26 | — | — | US | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| US-12616692-B2 | Method of achieving HIV viral remission using long-acting antiretroviral agents | ViiV Healthcare Company; and (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260103525-A1 | KLRG1 SIGNALLING THERAPY FOR INFECTIOUS DISEASE | BRIGHAM & WOMENS HOSPITAL INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4720056-A1 | SOLID FORMS OF COMPOUNDS USEFUL IN THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | claimed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| US-11248005-B2 | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor | LUPIN LIMITED (IN) | 2022-02-15 | — | — | US | claimed |
| US-20220024970-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2022-01-27 | — | — | US | claimed |
| EP-2465580-B1 | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity | VIIV HEALTHCARE CO (US) | 2013-12-18 | — | — | EP | claimed |
| US-8410103-B2 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2013-04-02 | — | — | US | claimed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | claimed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | claimed |
| EP-1874117-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SmithKline Beecham Corporation (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006116764-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636285-B2 | Method for treating HIV with cabotegravir and rilpivirine | IL2, JAK1, IL6 | SLC22A2 1489/4885CYP3A4 23/4885TMEM97 1254/4885 |
| US-11248005-B2 | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor | SAMHD1, TYMS, DUT | SLC22A2 4126/4885CYP3A4 11/4885TMEM97 3589/4885 |
| US-20220024970-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | ERG28, ZC3HAV1, FURIN | SLC22A2 4242/4885CYP3A4 202/4885TMEM97 2483/4885 |
| US-12616692-B2 | Method of achieving HIV viral remission using long-acting antiretroviral agents | CD4, HAVCR2, NECTIN4 | SLC22A2 1783/4885CYP3A4 22/4885TMEM97 1278/4885 |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | IRF3, STING1, MAVS | SLC22A2 3484/4885CYP3A4 3581/4885TMEM97 2497/4885 |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
| US-11253499-B2 | Compounds | SDHA, SDHB, FDPS | SLC22A2 938/4885CYP3A4 502/4885TMEM97 2338/4885 |
| US-11254689-B2 | Compounds | SDHA, SDHB, FDPS | SLC22A2 938/4885CYP3A4 502/4885TMEM97 2338/4885 |
| US-12636286-B2 | Method for treating HIV with cabotegravir and rilpivirine | IL2, IL4, IL5 | SLC22A2 2631/4885CYP3A4 22/4885TMEM97 1217/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
| US-20260103525-A1 | KLRG1 SIGNALLING THERAPY FOR INFECTIOUS DISEASE | HAVCR2, KLRK1, IGSF11 | SLC22A2 1964/4885CYP3A4 4060/4885TMEM97 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.